Advanced search×

Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients.

Muriel M Duclos, Laure L Gossec, Adeline A Ruyssen-Witrand, Carine C Salliot, Mathieu M Luc, Sandra S Guignard, and Maxime M Dougados

Journal Watch (General) 33(12):2433-8 (2006) PMID 17014004

Tumor necrosis factor (TNF) blockers are efficacious in clinical trials in rheumatic diseases. However, their efficacy in daily practice, depending on the specific diagnosis or the use of concomitant therapy, remains to be confirmed. Our objective was to evaluate TNF blocker retention rates and their predisposing factors in daily practice.

Version: za2963e q8zae q8zb8 q8zc6 q8zde q8ze7 q8zfe q8zg5

Similar articles you may find interesting…

  1. Development and validation of a preference weight multiattribute health outcome measure for rheumatoid arthritis.
    Chiun-Fang CF Chiou, Maria E ME Suarez-Almazor, ... Michael M Weisman

    Journal Watch (General) 33(12):2409-11 (2006) PMID 17080516

    Four hundred eighty-seven patients returned the survey; 24 items on 6 health attributes were selected to form the new outcomes measure. Two MAPWF were derived with preference weights measured with time tradeoff and visual analog scales as dependent variables. All validity test results were statistic...